Imatinib Mesylate
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
... Imatinib mesylate was obtained from Ranbaxy Pharmaceuti- cals (Delhi, India). PLGA (acid-terminated; lactide:glycolide 50:50; Mw [molecular weight] 24,000–38,000 D), polyvinyl alcohol (PVA; Mw 31,000–50,000 ...
8
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
... arthritis. Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor developed to treat Bcr/Abl-expressing leukemias and subsequently found to treat c-Kit–expressing gastrointestinal stromal ...
11
DEVELOPMENT, EVALUATION AND TARGETING OF IMATINIB MESYLATE LOADED SOLID LIPID NANOPARTICLES TO THE LYMPHATIC SYSTEM
... . Imatinib mesylate is an anti-neoplastic agent for the treatment of acute lymphoblastic leukemia/ lymphoma, acts by inhibiting the protein tyrosine kinase, responsible for the proliferation of ...
10
METHOD DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING RP HPLC METHOD FOR ASSAY DETERMINATION OF IMATINIB IN IMATINIB MESYLATE TABLETS DOSAGE FORM
... CONCLUSION: An isocratic RP-HPLC assay method is successfully developed and validated for the determination of Imatinib in Imatinib mesylate tablet dosage form. The method is evaluated for all method ...
16
LC-MS/MS method for determination of potential genotoxic impurities in imatinib mesylate
... benzoic acid dihydrochloride(MPBA) content in Imatinib Mesylate on YMC –Basic, 250 X 4.6 mm 5 µ m column using a gradient mixture of solvent A ( 10mM ammonium formate , adjust the pH of the above solution ...
6
Efficacy and Tolerability of Imatinib Mesylate In Advanced Gastrointestinal Stromal Tumors
... Imatinib mesylate is a selective inhibitor of certain protein tyrosine kinases: the intracellular ABL kinase, the chimeric BCR-ABL fusion oncoprotein of chronic myeloid leukemia, the trans-membrane receptor ...
6
Original Article Imatinib mesylate induces apoptosis of K562 cell by down-regulating miR-139
... of imatinib mesylate-in- duced apoptosis had been eluci- ...undergone imatinib mesylate treatment or animal model has been tested for in vivo cell apoptosis or miR- 139 ...by imatinib ...
7
Development of UV-Spectrophotometric Method for the Determination of Imatinib Mesylate (ITM) In Bulk and Formulation
... The precision was measured in terms of repeatability, which was determined by sufficient number of aliquots of a homogeneous sample. The % RSD was found and lie within the range of ± 2.0. This showed that the precision ...
6
PHARMACEUTICAL EVALUATION OF DIFFERENT TABLET BRANDS OF LETROZOLE AND IMATINIB MESYLATE MARKETED IN LIBYA
... of Imatinib mesylate tablets were found at the lower Pharmacopoeial limit for drug dissolution and failed to meet the dissolution requirement of the respective drug class in Biopharmaceutical classification ...
20
Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
... that imatinib-sensitive patients had a lower SIRT1 gene ...receiving imatinib mesylate for a couple of years; while previous studies were conducted on fewer patients or mostly focused on laboratory ...
7
Preparation and Evaluation of Nanoparticles Containing Imatinib Mesylate and the Complex of Imatinib Mesylate Cobalt (II) Chloride
... Imatinib Mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr- abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in Chronic ...
167
<p>Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review</p>
... since imatinib mesylate has been proven effective to ...evidence, imatinib mesylate showed a signi fi cantly bene fi cial outcome as an adjuvant pre- and post-surgery therapy for advanced ...of ...
5
Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
... Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia A Local Experience ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia A Local Experience PC Bee, MMed*, G G[.] ...
6
Inhibition of the platelet derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
... Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity resistant to chemotherapy. The identification of novel therapeutic targets is needed to improve its poor prognosis. Following a review of literature ...
17
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
... regard imatinib, Bertino and co-workers [2], have reported that this drug has the ability to induce cytotoxicity and apoptosis selectively on PDGFRB positive MPM cells via blockade of receptor phosphorylation and ...
15
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
... advanced non-metastatic GIST patients [16]. An inter- esting question is whether recurrent or metastatic patients with a good response to imatinib will receive any further benefit from surgical resection. Given ...
7
Periorbital edema secondary to imatinib mesylate
... of imatinib treatment several years prior to ...of imatinib was increased from 400 to 600 mg per day in order to induce remission of accelerated ...her imatinib dose, the patient reported severe ...
5
Response to Imatinib Mesylate in patients with Chronic Myeloid Leukemia.
... of Imatinib on developing infant is ...receiving Imatinib for the treatment of CML were followed ...with Imatinib, eight patients had a cytogenetic response (complete in three ...
71
Gastrointestinal stromal tumors: three decades of lessons
... like imatinib mesylate that inhibits activation of the KIT and PDGFα proteins by binding to the adenosine triphosphate binding pocket required for receptor phosphorylation and ...
10
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
... The expansion cohort used the MTD determined by the dose escalation study to treat patients with KIT -mutant or c-KIT expressing solid tumors. Use of previously obtained tumor biopsy/tissue specimens was acceptable. KIT ...
10